<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050687</url>
  </required_header>
  <id_info>
    <org_study_id>TTP-370-01-01</org_study_id>
    <nct_id>NCT00050687</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies</brief_title>
  <official_title>A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Titan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Titan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerance, and efficacy of different doses of oral gallium&#xD;
      maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days&#xD;
      followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will&#xD;
      be assessed and the levels of gallium in serum will be measured. Any effect of the drug on&#xD;
      the cancer and any improvement in cancer-related symptoms will also be measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gallium maltolate is an orally bioavailable form of gallium. This is a safety,&#xD;
      pharmacokinetic and preliminary efficacy study. The primary objective of the study is to&#xD;
      assess the safety profile in patients after oral administration of different doses of gallium&#xD;
      maltolate for up to six 42-day cycles (28 days of gallium maltolate, followed by 14 days off&#xD;
      treatment). In addition, serum concentrations of gallium and associated pharmacokinetic&#xD;
      variables will be measured. From this information, an optimal dose will be selected for&#xD;
      assessment of anti-tumor efficacy. The study assesses the effects of oral administration of&#xD;
      gallium maltolate on pain resulting from bony metastasis, on biochemical measures of bone&#xD;
      turnover, and on disease progression and overall survival in patients with various refractory&#xD;
      malignancies. Patients may receive up to 6 cycles of the investigational agent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostatic Neoplasms</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Bladder Neoplasms</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium maltolate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hormone refractory prostate cancer, refractory multiple myeloma,&#xD;
             refractory bladder cancer, or malignant lymphoma;&#xD;
&#xD;
          -  life expectancy of ≥6 months,&#xD;
&#xD;
          -  Zubrod Performance Status of ≤2,&#xD;
&#xD;
          -  adequate bone marrow function, renal function, liver function and pulmonary function;&#xD;
&#xD;
          -  age ≥ 18 years;&#xD;
&#xD;
          -  willing and able to give informed consent; and&#xD;
&#xD;
          -  effective contraceptive use or non child-bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  10% weight loss in the previous 3 months;&#xD;
&#xD;
          -  active serious infection not controlled by antibiotics;&#xD;
&#xD;
          -  initiation of bisphosphonates treatment within 30 days;&#xD;
&#xD;
          -  participation in other research study within 30 days;&#xD;
&#xD;
          -  uncontrolled brain metastasis,&#xD;
&#xD;
          -  prior intrathecal chemotherapy or whole-brain radiotherapy,&#xD;
&#xD;
          -  inability to comply with protocol or undergo specified tests;&#xD;
&#xD;
          -  other active malignancy;&#xD;
&#xD;
          -  optic neuritis, and&#xD;
&#xD;
          -  routine use of diuretics (for initial phase of study only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Highlands Oncology Group, PA</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Care</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southfield Oncology Institute</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>December 17, 2002</study_first_submitted>
  <study_first_submitted_qc>December 18, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2002</study_first_posted>
  <disposition_first_submitted>January 11, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 21, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2011</disposition_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

